Scholarlink

Introduction <p>We aimed to investigate the effects of clinical and laboratory characteristics before neoadjuvant chemotherapy (NAC) on prognosis and the relationship between the number of NAC cycles and overall survival (OS) and disease-free survival (DFS) in patients with advanced ovarian cancer.</p> Methods <p>The records of 135 patients with epithelial ovarian cancer (EOC) who were not suitable for surgery at the time of diagnosis and who received neoadjuvant treatment were retrospectively analyzed. The Kaplan–Meier method and log-rank test were used for survival analyses. In all analyses, <i>p</i> value &lt; 0.05 was considered statistically significant.</p> Results <p>Estrogen receptor (ER)-negative patients had shorter survival times compared to ER-positive patients. Patients with paraaortic lymph node involvement had shorter survival (*<i>P</i> &lt; 0.05). As NLR (neutrophil/lymphocyte ratio) increased, survival time was found to shorten (*<i>P</i> &lt; 0.05). Patients who received three or fewer courses of neoadjuvant chemotherapy had a median survival time (mOS) of 60&#xa0;months, while patients who received more than three courses had a mOS of 40&#xa0;months. While a numerical difference was observed between both groups in terms of survival time, no statistically significant difference was found (*<i>P</i> = 0.05). Although there was a numerical difference in DFS between the two groups, there was no statistically significant difference (<i>P</i> = 0.651).</p> Conclusions <p>In our study, ECOG performance status, estrogen receptor status, NLR and paraaortic lymph node involvement were found to be associated with OS in patients with advanced EOC who underwent interval debulking after neoadjuvant treatment. No significant correlation was found between the number of NACs and OS and DFS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival-Related Prognostic Factors in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy

  • 期刊论文

  • 发表日期：

    2025年8月13日

查看全文
  • Mehmet Uzun,
  • Kubra Canaslan,
  • Eda Caliskan Yildirim,
  • Savas Gokcek,
  • Erhan Kaya,
  • Elif Atag,
  • Huseyin Salih Semiz

摘要

Introduction

We aimed to investigate the effects of clinical and laboratory characteristics before neoadjuvant chemotherapy (NAC) on prognosis and the relationship between the number of NAC cycles and overall survival (OS) and disease-free survival (DFS) in patients with advanced ovarian cancer.

Methods

The records of 135 patients with epithelial ovarian cancer (EOC) who were not suitable for surgery at the time of diagnosis and who received neoadjuvant treatment were retrospectively analyzed. The Kaplan–Meier method and log-rank test were used for survival analyses. In all analyses, p value < 0.05 was considered statistically significant.

Results

Estrogen receptor (ER)-negative patients had shorter survival times compared to ER-positive patients. Patients with paraaortic lymph node involvement had shorter survival (*P < 0.05). As NLR (neutrophil/lymphocyte ratio) increased, survival time was found to shorten (*P < 0.05). Patients who received three or fewer courses of neoadjuvant chemotherapy had a median survival time (mOS) of 60 months, while patients who received more than three courses had a mOS of 40 months. While a numerical difference was observed between both groups in terms of survival time, no statistically significant difference was found (*P = 0.05). Although there was a numerical difference in DFS between the two groups, there was no statistically significant difference (P = 0.651).

Conclusions

In our study, ECOG performance status, estrogen receptor status, NLR and paraaortic lymph node involvement were found to be associated with OS in patients with advanced EOC who underwent interval debulking after neoadjuvant treatment. No significant correlation was found between the number of NACs and OS and DFS.